4//SEC Filing
Pontifax (Cayman) IV L.P. 4
Accession 0001209191-18-027114
CIK 0001035354other
Filed
Apr 30, 8:00 PM ET
Accepted
May 1, 4:37 PM ET
Size
17.9 KB
Accession
0001209191-18-027114
Insider Transaction Report
Form 4
Pontifax (Cayman) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2018-04-30$9.75/sh+172,626$1,683,104→ 962,504 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+84,041$819,400→ 468,585 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+93,333$909,997→ 520,396 total(indirect: By Pontifax Investment Fund)
Pontifax IV GP L.P.
10% Owner
Transactions
- Purchase
Common Stock
2018-04-30$9.75/sh+172,626$1,683,104→ 962,504 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+93,333$909,997→ 520,396 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+84,041$819,400→ 468,585 total(indirect: By Pontifax Investment Fund)
Transactions
- Purchase
Common Stock
2018-04-30$9.75/sh+84,041$819,400→ 468,585 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+172,626$1,683,104→ 962,504 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+93,333$909,997→ 520,396 total(indirect: By Pontifax Investment Fund)
Pontifax (China) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2018-04-30$9.75/sh+84,041$819,400→ 468,585 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+93,333$909,997→ 520,396 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+172,626$1,683,104→ 962,504 total(indirect: By Pontifax Investment Fund)
Pontifax (Israel) IV, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2018-04-30$9.75/sh+93,333$909,997→ 520,396 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+84,041$819,400→ 468,585 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2018-04-30$9.75/sh+172,626$1,683,104→ 962,504 total(indirect: By Pontifax Investment Fund)
Footnotes (4)
- [F1]Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.
- [F2]Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F3]Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F4]Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Documents
Issuer
Eloxx Pharmaceuticals, Inc.
CIK 0001035354
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001726029
Filing Metadata
- Form type
- 4
- Filed
- Apr 30, 8:00 PM ET
- Accepted
- May 1, 4:37 PM ET
- Size
- 17.9 KB